Peri-operative Oral Triiodothyronine Replacement Therapy to Decrease the Risk of Transient Atrial Fibrillation After Off-pump Coronary Artery Bypass Surgery
Not Applicable
Completed
- Conditions
- Non-thyroidal Illness Syndrome
- Interventions
- Drug: placebo
- Registration Number
- NCT01153360
- Lead Sponsor
- Yonsei University
- Brief Summary
This study is planned to medicate oral T3(Liothyronine)to the patients who are planned to have OPCAB(off- pump coronary bypass graft surgery. The aim of this study was to assess the effects of oral triiodothyronine (T3) therapy on postoperative thyroid hormone concentrations, hemodynamic variables and outcomes in patients undergoing OPCAB in a randomized, controlled trial.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Patients who are undergoing Off-pump coronary artery bypass graft
Exclusion Criteria
- No normal sinus rhythm,
- History of thyroid disease
- Abnormal thyroid hormone
- Renal dysfunction
- Hepatic dysfunction
- LVEF <30%
- Recent MI
- Active infection 1~15
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description T3 liothyronine sodium triiodothyronine cyanocobalamin placebo vitamin B12
- Primary Outcome Measures
Name Time Method compare the serum T3 concentrations and the number of patients with serum T3 concentrations below the normal range between the groups until 36 hours after surgery
- Secondary Outcome Measures
Name Time Method difference of hemodynamic performance and myocardial injury during surgery and 36 hr after surgery difference of hemodynamic performance and myocardial injury between the groups
Trial Locations
- Locations (1)
Severance Hospital
🇰🇷Seoul, Korea, Republic of